The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | NI-HEART study results: cardiotoxicity after lung cancer radiotherapy
Gerard Walls, MB MRCP MSc FRCR, Queens University in Belfast, UK, discusses key findings from the NI-HEART analysis focusing on cardiotoxicity events after radiotherapy for lung cancer. The analysis explored the potential benefits of statin therapy in reducing cardiotoxicity events post-treatment, revealing an association between statin use and improved overall survival (OS). Additionally, the study investigated the impact of radiation dose on pulmonary veins, identifying a correlation between higher doses and increased risk of atrial fibrillation. Furthermore, validation of the Manchester data regarding the heart base region showed that higher doses to this area were associated with cardiac events like heart attacks and heart failure. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
